These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16032760)

  • 1. A rapid and simple HPLC-UV method for the determination of inhibition characteristics of farnesyl transferase inhibitors.
    Appels NM; Tung KO; Rosing H; Schellens JH; Beijnen JH
    Biomed Chromatogr; 2006 Feb; 20(2):161-5. PubMed ID: 16032760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cell-based radioligand binding assay for farnesyl: protein transferase inhibitors.
    Lobell RB; Davide JP; Kohl NE; Burns HD; Eng WS; Gibson RE
    J Biomol Screen; 2003 Aug; 8(4):430-8. PubMed ID: 14567795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid posttranslational modifications. Farnesyl transferase inhibitors.
    Basso AD; Kirschmeier P; Bishop WR
    J Lipid Res; 2006 Jan; 47(1):15-31. PubMed ID: 16278491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absolute quantification of farnesylated Ras levels in complex samples using liquid chromatography fractionation combined with tryptic digestion and electrospray tandem mass spectrometry.
    Appels NM; Rosing H; Stephens TC; Hughes A; Schellens JH; Beijnen JH
    Anal Biochem; 2006 May; 352(1):33-40. PubMed ID: 16564488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Farnesyl transferase inhibitors--a novel agent for breast cancer].
    Zhang M; Jiang D
    Ai Zheng; 2006 Apr; 25(4):516-20. PubMed ID: 16613692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives on farnesyl transferase inhibitors in cancer therapy.
    Mazieres J; Pradines A; Favre G
    Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using inhibitors of prenylation to block localization and transforming activity.
    Berzat AC; Brady DC; Fiordalisi JJ; Cox AD
    Methods Enzymol; 2006; 407():575-97. PubMed ID: 16757354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible inactivation of the transcriptional function of P53 protein by farnesylation.
    Couderc B; Penary M; Tohfe M; Pradines A; Casteignau A; Berg D; Favre G
    BMC Biotechnol; 2006 May; 6():26. PubMed ID: 16732889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors.
    Pan J; Yeung SC
    Cancer Res; 2005 Oct; 65(20):9109-12. PubMed ID: 16230362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
    Feldkamp MM; Lau N; Roncari L; Guha A
    Cancer Res; 2001 Jun; 61(11):4425-31. PubMed ID: 11389071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome.
    Efuet ET; Keyomarsi K
    Cancer Res; 2006 Jan; 66(2):1040-51. PubMed ID: 16424040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The farnesyltransferase inhibitor, LB42708, inhibits growth and induces apoptosis irreversibly in H-ras and K-ras-transformed rat intestinal epithelial cells.
    Kim HS; Kim JW; Gang J; Wen J; Koh SS; Koh JS; Chung HH; Song SY
    Toxicol Appl Pharmacol; 2006 Sep; 215(3):317-29. PubMed ID: 16712893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel triazole based inhibitors of Ras farnesyl transferase.
    Saha AK; Liu L; Simoneaux R; DeCorte B; Meyer C; Skrzat S; Breslin HJ; Kukla MJ; End DW
    Bioorg Med Chem Lett; 2005 Dec; 15(24):5407-11. PubMed ID: 16216509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spongolactams, farnesyl transferase inhibitors from a marine sponge: isolation through an LC/MS-guided assay, structures, and semisyntheses.
    Mori D; Kimura Y; Kitamura S; Sakagami Y; Yoshioka Y; Shintani T; Okamoto T; Ojika M
    J Org Chem; 2007 Sep; 72(19):7190-8. PubMed ID: 17713950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of farnesyltransferase inhibitors in hematologic malignancies.
    Santos ES; Rosenblatt JD; Goodman M
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):843-56. PubMed ID: 15485318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of farnesylmethylcysteine in lysates of peripheral blood mononuclear cells using liquid chromatography coupled with electrospray tandem mass spectrometry: pharmacodynamic assay for farnesyl transferase inhibitors.
    Appels NM; Rosing H; Stephens TC; Schellens JH; Beijnen JH
    Anal Chem; 2006 Apr; 78(8):2617-22. PubMed ID: 16615771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory activity of 6-O-angeloylprenolin from Centipeda minima on farnesyl protein transferase.
    Oh HM; Kwon BM; Baek NI; Kim SH; Lee JH; Eun JS; Yang JH; Kim DK
    Arch Pharm Res; 2006 Jan; 29(1):64-6. PubMed ID: 16491845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of farnesyl transferase inhibitors: a review.
    Appels NM; Beijnen JH; Schellens JH
    Oncologist; 2005 Sep; 10(8):565-78. PubMed ID: 16177281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyltransferase inhibitors target multiple endothelial cell functions in angiogenesis.
    Scott AN; Hetheridge C; Reynolds AR; Nayak V; Hodivala-Dilke K; Mellor H
    Angiogenesis; 2008; 11(4):337-46. PubMed ID: 18758974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesyl transferase inhibitors in myeloid disorders.
    Lancet JE; Karp JE
    Oncology (Williston Park); 2005 Jul; 19(8):1043-9; discussion 1049-50, 1053-4. PubMed ID: 16131046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.